Meilan K Han

List of Publications by Year
in descending order

263 papers	19,090 citations	16437 64 h-index	14197 128 g-index
276 all docs	276 docs citations	276 times ranked	15528 citing authors

#	Article	IF	Citations
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	3.1	1,223
2	Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011, 365, 689-698.	13.9	1,057
3	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	2.5	898
4	Analysis of the Lung Microbiome in the â€œHealthyâ€•Smoker and in COPD. PLoS ONE, 2011, 6, e16384.	1.1	767
5	Computed tomographyâ€"based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nature Medicine, 2012, 18, 1711-1715.	15.2	619
6	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. New England Journal of Medicine, 2016, 374, 1811-1821.	13.9	526
7	Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respiratory Medicine,the, 2013, 1, 309-317.	5.2	486
8	Pulmonary Arterial Enlargement and Acute Exacerbations of COPD. New England Journal of Medicine, 2012, 367, 913-921.	13.9	397
9	Chronic Obstructive Pulmonary Disease Exacerbations in the COPDGene Study: Associated Radiologic Phenotypes. Radiology, 2011, 261, 274-282.	3.6	373
10	Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Internal Medicine, 2015, 175, 1539.	2.6	360
11	Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respiratory Medicine,the, 2014, 2, 548-556.	5.2	353
12	Sex Differences in Severe Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 243-252.	2.5	301
13	Gender and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1179-1184.	2.5	293
14	Association between Functional Small Airway Disease and FEV_1 Decline in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 178-184.	2.5	292
15	The Chronic Bronchitic Phenotype of COPD. Chest, 2011, 140, 626-633.	0.4	280
16	Airway Mucin Concentration as a Marker of Chronic Bronchitis. New England Journal of Medicine, 2017, 377, 911-922.	13.9	279
17	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): TableÂ1. Thorax, 2014, 69, 492-495.	2.7	277
18	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 619-626.	5.2	219

#	Article	IF	Citations
19	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 956-967.	5.2	211
20	GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respiratory Medicine,the, 2013, 1, 43-50.	5.2	209
21	Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1127-1138.	2.5	205
22	Sildenafil Preserves Exercise Capacity in Patients With Idiopathic Pulmonary Fibrosis and Right-sided Ventricular Dysfunction. Chest, 2013, 143, 1699-1708.	0.4	196
23	Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respiratory Research, 2014, 15, 89.	1.4	196
24	Significance of the microbiome in obstructive lung disease. Thorax, 2012, 67, 456-463.	2.7	190
25	Computed Tomographic Measures of Pulmonary Vascular Morphology in Smokers and Their Clinical Implications. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 231-239.	2.5	188
26	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	2.5	185
27	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 794-806.	2.5	180
28	Pulmonary Diseases and the Heart. Circulation, 2007, 116, 2992-3005.	1.6	177
29	Spirometry Utilization for COPD. Chest, 2007, 132, 403-409.	0.4	165
30	MMP Mediated Degradation of Type IV Collagen Alpha 1 and Alpha 3 Chains Reflects Basement Membrane Remodeling in Experimental and Clinical Fibrosis â€" Validation of Two Novel Biomarker Assays. PLoS ONE, 2013, 8, e84934.	1.1	145
31	CT-based Visual Classification of Emphysema: Association with Mortality in the COPDGene Study. Radiology, 2018, 288, 859-866.	3.6	138
32	Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality. Annals of the American Thoracic Society, 2015, 12, 1788-1795.	1.5	135
33	Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory Medicine, 2020, 166, 105938.	1.3	135
34	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1397-1405.	2.5	132
35	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 208-219.	2.5	130
36	Chronic respiratory diseases: a global view. Lancet Respiratory Medicine,the, 2020, 8, 531-533.	5.2	130

#	ARTICLE	IF	CITATIONS
37	Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax, 2014, 69, 416-423.	2.7	128
38	Quantitative Computed Tomography of the Lungs and Airways in Healthy Nonsmoking Adults. Investigative Radiology, 2012, 47, 596-602.	3.5	121
39	From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 414-423.	2.5	119
40	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax, 2014, 69, 987-996.	2.7	114
41	COPDGeneÂ® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 384-399.	0.5	112
42	Metoprolol for the Prevention of Acute Exacerbations of COPD. New England Journal of Medicine, 2019, 381, 2304-2314.	13.9	111
43	Women and Lung Disease. Sex Differences and Global Health Disparities. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 11-16.	2.5	110
44	Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 575-581.	2.5	110
45	Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax, 2012, 67, 399-406.	2.7	108
46	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA - Journal of the American Medical Association, 2020, 323, 2268.	3.8	104
47	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	2.5	101
48	A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 748-756.	2.5	100
49	The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1372-1379.	2.5	97
50	Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. Respiratory Research, 2013, 14, 42.	1.4	93
51	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	1.5	88
52	Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. Respiratory Research, 2014, 15, 52.	1.4	86
53	Parametric Response Mapping Monitors Temporal Changes on Lung CT Scans in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Academic Radiology, 2015, 22, 186-194.	1.3	86
54	Improving the Management of COPD inÂWomen. Chest, 2017, 151, 686-696.	0.4	86

#	Article	IF	Citations
55	Clinical Significance of Radiologic Characterizations in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 459-467.	0.7	85
56	Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respiratory Medicine,the, 2016, 4, 473-526.	5.2	80
57	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E974-E981.	3.3	80
58	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2021, 9, 1241-1254.	5.2	80
59	An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. Journal of Clinical Investigation, 2018, 129, 169-181.	3.9	77
60	Superior Immune Response to Protein-Conjugate versus Free Pneumococcal Polysaccharide Vaccine in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 499-505.	2.5	76
61	Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 850-858.	2.5	74
62	Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. Journal of General Internal Medicine, 2017, 32, 1315-1322.	1.3	73
63	Arterial Vascular Pruning, Right Ventricular Size, and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. A Longitudinal Observational Study. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 454-461.	2.5	73
64	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
65	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. Chest, 2014, 146, 941-950.	0.4	71
66	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 957-968.	2.5	71
67	Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respiratory Research, 2020, 7, e000392.	1.2	69
68	The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respiratory Medicine, 2014, 108, 491-499.	1.3	65
69	Reconsidering the Utility of Race-Specific Lung Function Prediction Equations. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 819-829.	2.5	63
70	Machine Learning and Prediction of All-Cause Mortality in COPD. Chest, 2020, 158, 952-964.	0.4	62
71	Racial Differences in Quality of Life in Patients With COPD. Chest, 2011, 140, 1169-1176.	0.4	61
72	The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respiratory Research, 2014, 15, 127.	1.4	61

#	Article	IF	Citations
73	Impact of self-reported Gastroesophageal reflux disease in subjects from COPDGene cohort. Respiratory Research, 2014, 15, 62.	1.4	61
74	Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. Respiratory Research, 2013, 14, 13.	1.4	59
75	Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 464-472.	2.5	59
76	A Simplified Score to Quantify Comorbidity in COPD. PLoS ONE, 2014, 9, e114438.	1.1	58
77	Diffusing Capacity of Carbon Monoxide inÂAssessment of COPD. Chest, 2019, 156, 1111-1119.	0.4	58
78	Gender Differences in Symptoms and Care Delivery for Chronic Obstructive Pulmonary Disease. Journal of Women's Health, 2012, 21, 1267-1274.	1.5	57
79	Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions. Translational Research, 2017, 179, 71-83.	2.2	57
80	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 294-302.	2.5	56
81	Chronic Obstructive Pulmonary Disease, Cognitive Impairment, and Development of Disability: The Health and Retirement Study. Annals of the American Thoracic Society, 2014, 11, 1362-1370.	1.5	55
82	Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulmonary Medicine, 2014, 14, 164.	0.8	55
83	Sex-specific features of emphysema among current and former smokers with COPD. European Respiratory Journal, 2016, 47, 104-112.	3.1	55
84	Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. Academic Radiology, 2019, 26, 217-223.	1.3	55
85	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	3.1	53
86	Clinical Epidemiology of COPD. Chest, 2019, 156, 228-238.	0.4	53
87	Five-year Progression of Emphysema and Air Trapping at CT in Smokers with and Those without Chronic Obstructive Pulmonary Disease: Results from the COPDGene Study. Radiology, 2020, 295, 218-226.	3.6	52
88	Association Between Airway Caliber Changes With Lung Inflation and Emphysema Assessed by Volumetric CT Scan in Subjects With COPD. Chest, 2012, 141, 736-744.	0.4	50
89	Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. JAMA Internal Medicine, 2020, 180, 106.	2.6	49
90	Human CD56+ Cytotoxic Lung Lymphocytes Kill Autologous Lung Cells in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e103840.	1.1	48

#	ARTICLE	IF	CITATIONS
91	Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respiratory Research, 2015, 16, 94.	1.4	48
92	Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2014, 1, .	1.2	46
93	Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI Insight, 2018, 3, .	2.3	46
94	Handgrip Strength in Chronic Obstructive Pulmonary Disease. Associations with Acute Exacerbations and Body Composition. Annals of the American Thoracic Society, 2017, 14, 1638-1645.	1.5	44
95	Clinical Approach to the Therapy of Asthma-COPD Overlap. Chest, 2019, 155, 168-177.	0.4	44
96	Racial Differences in CT Phenotypes in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 20-27.	0.7	42
97	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 17-22.	2.5	42
98	Age-Related Differences in Health-Related Quality of Life in COPD. Chest, 2016, 149, 927-935.	0.4	41
99	Biomechanical CT metrics are associated with patient outcomes in COPD. Thorax, 2017, 72, 409-414.	2.7	41
100	Microbiome in interstitial lung disease. Current Opinion in Pulmonary Medicine, 2017, 23, 404-410.	1.2	41
101	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 721-731.	2.5	40
102	Comorbidities of COPD Have a Major Impact on Clinical Outcomes, Particularly in African Americans. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 105-114.	0.5	40
103	COPD Care in the 21st Century: A Public Health Priority. Respiratory Care, 2018, 63, 591-600.	0.8	39
104	Gender influences health-related Quality of Life in IPF. Respiratory Medicine, 2010, 104, 724-730.	1.3	38
105	The Effects of Rare <i>SERPINA1</i> Variants on Lung Function and Emphysema in SPIROMICS. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 540-554.	2.5	38
106	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 987-997.	2.5	38
107	Airway fractal dimension predicts respiratory morbidity and mortality in COPD. Journal of Clinical Investigation, 2018, 128, 5374-5382.	3.9	38
108	Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight from Screening Tools and Epidemiologic Studies. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 103-121.	0.5	38

#	ARTICLE	IF	CITATIONS
109	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight, 2020, 5, .	2.3	37
110	Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Review of Anti-Infective Therapy, 2006, 4, 101-124.	2.0	36
111	Contribution of the Environment and Comorbidities to Chronic Obstructive Pulmonary Disease Phenotypes. Medical Clinics of North America, 2012, 96, 713-727.	1.1	36
112	Chronic Obstructive Pulmonary Disease in America's Black Population. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 423-430.	2.5	36
113	Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction. Chest, 2021, 159, 1812-1820.	0.4	36
114	Advances in Chronic Obstructive Pulmonary Disease. Annual Review of Medicine, 2021, 72, 119-134.	5.0	33
115	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. Npj Biofilms and Microbiomes, 2021, 7, 14.	2.9	33
116	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 808-816.	1.5	32
117	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Annals of the American Thoracic Society, 2018, 15, 710-717.	1.5	32
118	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 14-23.	2.5	32
119	Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2017, 140, 1164-1167.e6.	1.5	31
120	Defining Impaired Respiratory Health. A Paradigm Shift for Pulmonary Medicine. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 440-446.	2.5	31
121	Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respiratory Research, 2018, 19, 30.	1.4	31
122	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. Annals of the American Thoracic Society, 2019, 16, 200-208.	1.5	31
123	Comprehensive stereological assessment of the human lung using multiresolution computed tomography. Journal of Applied Physiology, 2020, 128, 1604-1616.	1.2	31
124	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Annals of the American Thoracic Society, 2017, 14, 636-642.	1.5	30
125	Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. BMJ Open Respiratory Research, 2017, 4, e000252.	1.2	30
126	A digital protein microarray for COVID-19 cytokine storm monitoring. Lab on A Chip, 2021, 21, 331-343.	3.1	30

#	Article	IF	Citations
127	Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A *Post Hoc* Analysis of Two Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 265-267.	2.5	29
128	Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. European Respiratory Journal, 2019, 54, 1802214.	3.1	29
129	Relationship Between Lung Function Impairment and Health-Related Quality of Life in COPD and Interstitial Lung Disease. Chest, 2012, 142, 704-711.	0.4	28
130	Internet access and use by COPD patients in the National Emphysema/COPD Association Survey. BMC Pulmonary Medicine, 2014, 14, 66.	0.8	27
131	Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 1411-1419.	1.5	27
132	Adult Life-Course Trajectories of Lung Function and the Development of Emphysema: The CARDIA Lung Study. American Journal of Medicine, 2020, 133, 222-230.e11.	0.6	27
133	Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts. Radiology, 2021, 299, 222-231.	3.6	27
134	<p>The Association Between Neighborhood Socioeconomic Disadvantage and Chronic Obstructive Pulmonary Disease</p>. International Journal of COPD, 2020, Volume 15, 981-993.	0.9	27
135	Effect of Emphysema on CT Scan Measures of Airway Dimensions in Smokers. Chest, 2013, 143, 687-693.	0.4	26
136	CT-derived Biomechanical Metrics Improve Agreement Between Spirometry and Emphysema. Academic Radiology, 2016, 23, 1255-1263.	1.3	26
137	Improving Detection of Early Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2018, 15, S243-S248.	1.5	26
138	Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGeneÂ® Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 64-73.	0.5	26
139	The Impact of Sources of Variability on Parametric Response Mapping of Lung CT Scans. Tomography, 2015, 1, 69-77.	0.8	25
140	Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS ONE, 2018, 13, e0194924.	1.1	25
141	Aspirin Use and Respiratory Morbidity in COPD. Chest, 2019, 155, 519-527.	0.4	25
142	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatology, The, 2022, 4, e351-e361.	2.2	24
143	Serum IgG Levels and Risk of COPD Hospitalization. Chest, 2020, 158, 1420-1430.	0.4	22
144	Seven Pillars of Small Airways Disease in Asthma and COPD. Chest, 2021, 160, 114-134.	0.4	22

#	Article	IF	Citations
145	The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 177-185.	0.5	22
146	Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. BMJ Open Respiratory Research, 2017, 4, e000186.	1.2	21
147	New Spirometry Indices for Detecting Mild Airflow Obstruction. Scientific Reports, 2018, 8, 17484.	1.6	21
148	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Medicine, 2021, 13, 66.	3.6	21
149	Update in Chronic Obstructive Pulmonary Disease in 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1311-1315.	2.5	20
150	GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease. Respiratory Research, 2017, 18, 42.	1.4	20
151	Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. Respiratory Research, 2018, 19, 20.	1.4	20
152	Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. Scientific Reports, 2019, 9, 11367.	1.6	20
153	Respiratory exacerbations are associated with muscle loss in current and former smokers. Thorax, 2021, 76, 554-560.	2.7	20
154	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	1.1	20
155	Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD. Chest, 2022, 161, 1239-1249.	0.4	20
156	Clinical Correlations of Computed Tomography Imaging in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2013, 10, S131-S137.	1.5	19
157	Basal Gene Expression by Lung CD4+ T Cells in Chronic Obstructive Pulmonary Disease Identifies Independent Molecular Correlates of Airflow Obstruction and Emphysema Extent. PLoS ONE, 2014, 9, e96421.	1.1	19
158	Clinical Phenotypes of Atopy and Asthma in COPD. Chest, 2020, 158, 2333-2345.	0.4	19
159	Pharmacotherapeutic Approaches to Preventing Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2011, 8, 356-362.	3.5	18
160	Socioeconomic Characteristics Are Major Contributors to Ethnic Differences in Health Status in Obstructive Lung Disease. Chest, 2015, 148, 151-158.	0.4	18
161	Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort. Respiratory Research, 2018, 19, 257.	1.4	18
162	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. Chest, 2018, 154, 266-273.	0.4	18

#	Article	IF	Citations
163	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. Respiratory Medicine, 2018, 140, 87-93.	1.3	18
164	Systemic Markers of Inflammation in Smokers With Symptoms Despite PreservedÂSpirometry in SPIROMICS. Chest, 2019, 155, 908-917.	0.4	18
165	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. Annals of the American Thoracic Society, 2019, 16, 439-446.	1.5	18
166	Longitudinal Association Between Muscle Loss and Mortality in Ever Smokers. Chest, 2022, 161, 960-970.	0.4	18
167	Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. BMC Pulmonary Medicine, 2016, 16, 28.	0.8	17
168	<p>Disruption of histidine and energy homeostasis in chronic obstructive pulmonary disease</p>. International Journal of COPD, 2019, Volume 14, 2015-2025.	0.9	17
169	<p>Chronic Obstructive Pulmonary Disease in Women: A Biologically Focused Review with a Systematic Search Strategy</p>. International Journal of COPD, 2020, Volume 15, 711-721.	0.9	17
170	Older Adults with Chronic Lung Disease Report Less Limitation Compared with Younger Adults with Similar Lung Function Impairment. Annals of the American Thoracic Society, 2015, 12, 21-26.	1.5	16
171	<p>Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis</p>. International Journal of COPD, 2019, Volume 14, 2927-2938.	0.9	16
172	Lung Mass in Smokers. Academic Radiology, 2017, 24, 386-392.	1.3	15
173	Practical Considerations for the Diagnosis and Management of Asthma in Older Adults. Mayo Clinic Proceedings, 2017, 92, 1697-1705.	1.4	15
174	Pulmonary artery enlargement and mortality risk in moderate to severe COPD: results from COPDGene. European Respiratory Journal, 2020, 55, 1901812.	3.1	15
175	DNA Methylation Is Predictive of Mortality in Current and Former Smokers. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1099-1109.	2.5	15
176	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax, 2016, 71, 411-420.	2.7	14
177	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. Scientific Reports, 2020, 10, 10562.	1.6	14
178	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. Respiratory Research, 2021, 22, 126.	1.4	14
179	Insight into Best Variables for COPD Case Identification: A Random Forests Analysis. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 406-418.	0.5	13
180	Association between acute respiratory disease events and the <i>MUC5B</i> promoter polymorphism in smokers. Thorax, 2018, 73, 1071-1074.	2.7	13

#	Article	IF	Citations
181	Artificial Intelligence and Chest Imaging. Will Deep Learning Make Us Smarter?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 148-150.	2.5	13
182	Improved detection of air trapping on expiratory computed tomography using deep learning. PLoS ONE, 2021, 16, e0248902.	1.1	13
183	Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers. Korean Journal of Radiology, 2019, 20, 1236.	1.5	13
184	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. Respiratory Research, 2018, 19, 223.	1.4	12
185	Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?. International Journal of COPD, 2018, Volume 13, 1901-1912.	0.9	12
186	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Scientific Reports, 2021, 11, 4916.	1.6	12
187	Reprint of: Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. Academic Radiology, 2019, 26, 306-312.	1.3	11
188	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	1.5	11
189	Modeling residential indoor concentrations of $PM_{2.5}$, NO_2, NO_x, and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study. Indoor Air, 2021, 31, 702-716.	2.0	11
190	Identifying Smoking-Related Disease on Lung Cancer Screening CT Scans: Increasing the Value. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 233-245.	0.5	11
191	Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 554-562.	2.5	11
192	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020.	1.1	10
193	Paired CT Measures of Emphysema and Small Airways Disease and Lung Function and Exercise Capacity in Smokers with Radiographic Bronchiectasis. Academic Radiology, 2021, 28, 370-378.	1.3	10
194	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy, 2022, 39, 3957-3978.	1.3	10
195	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respiratory Medicine, 2016, 111, 30-38.	1.3	9
196	Objectively Measured Chronic Lung InjuryÂon Chest CT. Chest, 2019, 156, 1149-1159.	0.4	9
197	Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort. Chest, 2021, 160, 1245-1254.	0.4	9
198	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. Science of the Total Environment, 2022, 829, 154694.	3.9	9

#	Article	IF	Citations
199	COPD in 2016: some answers, more questions. Lancet Respiratory Medicine,the, 2016, 4, 941-943.	5.2	8
200	Antibiotics for COPD exacerbations. Lancet Respiratory Medicine,the, 2017, 5, 461-462.	5.2	8
201	Effect of daily azithromycin therapy and adherence on readmission risk in COPD. European Respiratory Journal, 2019, 53, 1801377.	3.1	8
202	The Peak Index: Spirometry Metric for Airflow Obstruction Severity and Heterogeneity. Annals of the American Thoracic Society, 2019, 16, 982-989.	1.5	8
203	Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. Scientific Reports, 2020, 10, 20133.	1.6	8
204	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). International Journal of COPD, 2021, Volume 16, 1477-1496.	0.9	8
205	Ratio of FEV1/Slow Vital Capacity of< 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function. Chest, 2021, 160, 94-103.	0.4	8
206	Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 60-75.	0.5	8
207	Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?. Current Opinion in Pulmonary Medicine, 2022, 28, 99-108.	1.2	8
208	Update in Chronic Obstructive Pulmonary Disease 2012. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 29-34.	2.5	7
209	COUNTERPOINT: Should Chest CT Be Part of Routine Clinical Care for COPD? No. Chest, 2018, 154, 1278-1281.	0.4	7
210	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	0.7	7
211	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research, 2021, 7, 00663-2020.	1.1	7
212	Progression of Emphysema and Small Airways Disease in Cigarette Smokers. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 198-212.	0.5	7
213	Comparative Impact of Depressive Symptoms and FEV$_1$% on Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2022, 19, 171-178.	1.5	7
214	The Association Between Lung Hyperinflation and Coronary Artery Disease in Smokers. Chest, 2021, 160, 858-871.	0.4	7
215	A controlled statistical study to assess measurement variability as a function of test object position and configuration for automated surveillance in a multicenter longitudinal COPD study (SPIROMICS). Medical Physics, 2016, 43, 2598-2610.	1.6	6
216	Confronting the Challenge of COPD. Chest, 2018, 154, 984-985.	0.4	6

#	Article	IF	Citations
217	Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPDGene Participants. Radiology, 2020, 296, 208-215.	3.6	6
218	Distinguishing Smoking-Related Lung Disease Phenotypes Via Imaging and Molecular Features. Chest, 2021, 159, 549-563.	0.4	6
219	Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease. ERJ Open Research, 2021, 7, 00068-2021.	1.1	6
220	Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD. Chest, 2022, 161, 949-959.	0.4	6
221	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 111-121.	0.5	6
222	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease. Respiratory Research, 2021, 22, 316.	1.4	6
223	Underutilization of Spirometry for the Diagnosis of COPD: Response. Chest, 2008, 133, 314.	0.4	5
224	GOLD COPD categories are not fit for purpose in primary care – Authors' reply. Lancet Respiratory Medicine,the, 2013, 1, e17-e18.	5.2	5
225	Factors influencing decline in quality of life in smokers without airflow obstruction: The COPDGene study. Respiratory Medicine, 2020, 161, 105820.	1.3	5
226	Defining Resilience to Smoking Related Lung Disease: A Modified Delphi Approach from SPIROMICS. Annals of the American Thoracic Society, 2021, 18, 1822-1831.	1.5	5
227	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 370-381.	0.5	5
228	Impact of bronchiectasis on the frequency and severity of respiratory exacerbations in COPD. International Journal of COPD, 2018, Volume 13, 2335-2338.	0.9	4
229	Update in Chronic Obstructive Pulmonary Disease 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1462-1470.	2.5	4
230	Impact of gastroesophageal reflux on longitudinal lung function and quantitative computed tomography in the COPDGene cohort. Respiratory Research, 2020, 21, 203.	1.4	4
231	Quantitative CT Correlates with Local Inflammation in Lung of Patients with Subtypes of Chronic Lung Allograft Dysfunction. Cells, 2022, 11, 699.	1.8	4
232	CT-Based Commercial Software Applications: Improving Patient Care Through Accurate COPD Subtyping. International Journal of COPD, 2022, Volume 17, 919-930.	0.9	4
233	Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respiratory Research, 2017, 18, 109.	1.4	3
234	Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD. Cellular and Molecular Bioengineering, 2019, 12, 165-177.	1.0	3

#	Article	IF	Citations
235	Reply to Janssen and Wouters: Loss of Alveolar Attachments as a Pathomechanistic Link between Small Airway Disease and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 879-880.	2.5	3
236	Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 329-337.	0.8	3
237	Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 135-151.	0.5	3
238	Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS. Tomography, 2017, 3, 138-145.	0.8	3
239	Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 210-220.	0.5	3
240	COPD. , 2016, , 767-785.e7.		2
241	Roflumilast for eosinophilic chronic obstructive pulmonary disease?. Lancet Respiratory Medicine,the, 2018, 6, 802-803.	5.2	2
242	Î²2 adrenergic receptor polymorphisms and COPD exacerbations: a complicated story. Thorax, 2019, 74, 927-928.	2.7	2
243	GOLD 2019: a new way forward. Lancet Respiratory Medicine,the, 2019, 7, 16-17.	5.2	2
244	<p>Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort</p>. International Journal of COPD, 2020, Volume 15, 1887-1898.	0.9	2
245	Lung Diseases Unique to Women. Clinics in Chest Medicine, 2021, 42, 507-516.	0.8	2
246	Developing and Implementing Biomarkers and Novel Imaging in COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 485-490.	0.5	2
247	Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 277-291.	0.5	1
248	Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, , .	0.5	1
249	Parturient Montes. Radiology, 2012, 262, 1042-1042.	3.6	0
250	Racial Differences Influence Health-Related Quality-of-Life Measurements: Response. Chest, 2012, 141, 571.	0.4	0
251	COPD treatment: time to change our algorithm?. Lancet Respiratory Medicine,the, 2013, 1, 176-177.	5.2	0
252	Women and COPD. Respiratory Medicine, 2016, , 63-85.	0.1	0

#	ARTICLE	IF	CITATIONS
253	Rebuttal From Dr Han. Chest, 2018, 154, 1282-1283.	0.4	0
254	The Exacerbation Conundrum. Archivos De Bronconeumologia, 2019, 55, 5-6.	0.4	0
255	The Exacerbation Conundrum. Archivos De Bronconeumologia, 2019, 55, 5-6.	0.4	0
256	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 326-335.	0.5	0
257	Reply to: Thomson, to Neder et al., and to Wouters. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 112.	2.5	0
258	Letter to Editor Regarding the OCEAN Study [Letter]. International Journal of COPD, 2021, Volume 16, 2501-2502.	0.9	0
259	X-ray dark field imaging: a tool for early diagnosis of emphysema in chronic obstructive pulmonary disease?. The Lancet Digital Health, 2021, 3, e691-e692.	5.9	0
260	Phenotypes of COPD. , 2017, , 147-168.		0
261	Understanding lung health beliefs in low-resource settings. The Lancet Global Health, 2022, 10, e6-e7.	2.9	0
262	Using Tools as Designed [Letter]. International Journal of COPD, 2022, Volume 17, 591-592.	0.9	0
263	Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin. Journal of Antimicrobial Chemotherapy, 0, , .	1.3	0